Suppr超能文献

应用染色细胞学直接涂片进行肺腺癌 ALK 基因重排分析。

The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.

机构信息

Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan.

出版信息

Cancer Cytopathol. 2013 Sep;121(9):489-99. doi: 10.1002/cncy.21286. Epub 2013 Mar 27.

Abstract

BACKGROUND

Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are present in approximately 5% of lung adenocarcinomas. Crizotinib is approved for the treatment of lung adenocarcinomas harboring ALK rearrangements. Patients with advanced stage lung cancer are not candidates for surgical resection of their primary tumors. For these patients, cytologic specimens often represent the only diagnostic tissue available. Cell blocks (CBs) are routinely used for molecular studies; however, insufficient CB cellularity can impede the performance of these assays.

METHODS

Thirty-two cytology cases of lung adenocarcinomas were analyzed by fluorescence in situ hybridization (FISH) for ALK rearrangements. Diff-Quik-stained smears were examined to identify tumor cell-enriched areas that were marked using a diamond-tipped scribe. Paired ALK rearrangement FISH was performed using smears and CBs in each case.

RESULTS

An ALK rearrangement was detected on direct smears and CB sections in 5 (16%) and 4 (13%), respectively, of the 32 cases studied. Concordant FISH results for smears and CBs were observed in 31 (97%) of 32 cases. In the 1 discordant case, an ALK rearrangement was detected on the direct smear but not in the CB. Reverse transcriptase-polymerase chain reaction analysis of this CB revealed the presence of an EML4-ALK rearrangement, thereby confirming a false-negative FISH result in the CB.

CONCLUSIONS

Stained cytologic direct smears can be effectively used for ALK rearrangement analysis by FISH. This approach represents a useful safeguard when insufficient CB cellularity is encountered and could prevent delays in treatment in this era of precision medicine.

摘要

背景

大约 5%的肺腺癌存在间变性淋巴瘤激酶(ALK)基因重排。克唑替尼获批用于治疗携带 ALK 重排的肺腺癌。晚期肺癌患者不符合手术切除其原发肿瘤的条件。对于这些患者,细胞学标本通常是唯一可用的诊断组织。细胞块(CB)通常用于分子研究;然而,CB 细胞数量不足会妨碍这些检测的进行。

方法

对 32 例肺腺癌的细胞学病例进行荧光原位杂交(FISH)分析,以检测 ALK 重排。用 Diff-Quik 染色的涂片检查以识别富含肿瘤细胞的区域,并使用钻石笔尖的划线器标记这些区域。在每个病例中,对涂片和 CB 进行配对的 ALK 重排 FISH。

结果

在所研究的 32 例病例中,直接涂片和 CB 切片分别检测到 5(16%)和 4(13%)例 ALK 重排。32 例病例中有 31 例(97%)的涂片和 CB 的 FISH 结果一致。在 1 例不一致的病例中,直接涂片上检测到 ALK 重排,但 CB 中未检测到。对该 CB 进行逆转录-聚合酶链反应分析显示存在 EML4-ALK 重排,从而证实 CB 中的 FISH 结果为假阴性。

结论

染色的细胞学直接涂片可有效地用于 FISH 分析 ALK 重排。当 CB 细胞数量不足时,这种方法是一种有用的保障措施,可防止在精准医学时代治疗延误。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验